Expression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions

Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.

Authors

Institutions

Publication Details

Journal
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Published
2026-11-14
DOI
https://doi.org/10.22141/2224-0721.22.7.2026.1777
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions

Н.І. Левчук, V.M. Pushkarev, P.P. Zinych, B.B. Guda et al.
1 links
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
Thyroid Cancer Diagnosis and Treatment
article

Expression of acid-sensing ion channel 1 in papillary thyroid carcinoma and metastatic lesions

Н.І. Левчук, V.M. Pushkarev, P.P. Zinych, B.B. Guda, О.І. Ковзун, M.V. Оstafiichuk
article en

Abstract

Background. Acid-sensing ion channel 1 (ASIC1) is a proton-gated cation channel encoded by the ASIC1 gene, one of five paralogous genes that form trimeric acid-sensing ion channels in mammals. An acidic extracellular microenvironment is a hallmark of solid tumors. ASIC1 is activated by extracellular acidification and functions as a key sensor of tumor acidosis. Increasing evidence indicates that ASIC1 contributes to multiple aspects of tumor biology, including cancer cell proliferation, migration, invasion, and metastatic dissemination. Aberrant ASIC1 expression has been reported in several malignancies, including hepatocellular, breast, gastric, brain and other cancers, suggesting that this ion channel may represent a novel biomarker and therapeutic target. The purpose was to investigate ASIC1 expression in conditionally normal thyroid tissue, primary papillary thyroid carcinoma (PTC), and metastatic lesions, and to evaluate its association with metastatic progression. Materials and methods. Postoperative samples of tissue were obtained from the surgical department of the clinic. The amount of ASIC1 was determined using enzyme immunoassay kits. Results. ASIC1 expression was significantly higher in primary PTC tissue without metastases than in adjacent conditionally normal tissue. Furthermore, tumors with lymph node metastases exhibited significantly greater ASIC1 expression than non-metastatic PTCs. The highest ASIC1 expression levels were detected in recurrent metastatic lesions, indicating a progressive increase in expression during tumor dissemination and recurrence. Conclusions. Elevated ASIC1 expression is associated with papillary thyroid carcinoma progression and metastatic potential. These findings suggest that ASIC1 may serve as a promising diagnostic biomarker for PTC and a potential predictor of metastatic spread, particularly recurrent metastasis. Further studies are warranted to clarify the mechanistic role of ASIC1 in thyroid cancer progression and to assess its value as a therapeutic target.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)Vol. 22(7)
V.P. Komisarenko Institute of Endocrinology and Metabolism (UA), National Academy of Medical Sciences of Ukraine (UA)
Good health and well-being
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon